Cardiovascular disease risk in Korean patients with systemic lupus erythematosus compared to diabetes mellitus and the general population

作     者：Han, Jung-Yong Cho, Soo-Kyung Jeon, Yena Kang, Gaeun Jung, Sun-Young Jang, Eun Jin Sung, Yoon-Kyoung 

作者机构：Hanyang Univ Hosp Rheumat Dis Dept Rheumatol Seoul 04763 South Korea Hanyang Univ Inst Rheumatol Res Seoul South Korea Kyungpook Natl Univ Dept Stat Daegu South Korea Chung Ang Univ Coll Pharm Seoul South Korea Andong Natl Univ Dept Informat Stat Andong South Korea 

出 版 物：《SCIENTIFIC REPORTS》 (Sci. Rep.)

年 卷 期：2025年第15卷第1期

页      面：1-10页

核心收录：

基　　金：Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF 2021R1A6A1A03038899] 

主　　题：Systemic lupus erythematosus Cardiovascular disease Diabetes mellitus 

摘      要：To evaluate the incidence and risk of cardiovascular disease (CVD) among Korean patients with systemic lupus erythematosus (SLE) comparing them to diabetes patients and the general population. This nationwide cohort study focused on incident SLE patients aged over 40 years, matched with diabetes patients and the general population (1:4:4 ratio). CVD was defined as ischaemic heart disease, ischaemic stroke, and cardiac arrest. Incidence rate and incidence rate ratio (IRR) of CVD were calculated using generalised estimating equation models. The Fine-Gray model assessed risk factors for CVD in both SLE and diabetes patients. The study included 4272 incident SLE patients, 17,003 diabetes patients, and 17,088 from the general population. SLE patients had higher CVD risk compared to the general population, with adjusted IRRs of 1.99 for overall CVD. Diabetes patients showed increased CVD risk, but to a lesser extent, with an IRR of 1.39. SLE patients aged 40-59 years displayed a significantly elevated CVD risk. Advanced age, male gender, and current use of glucocorticoids, immunosuppressive, and anti-platelet agents were associated with increased CVD risk in SLE patients. SLE patients have a higher risk of CVD compared to the general population, more so than diabetes patients.